Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease whose personalized clinical management requires robust molecular stratification. Here, we show that somatic hypermutation (SHM) patterns constitute a marker for DLBCL molecular classification. The activity of SHM ...
Diffuse large B cell lymphomaNon-Hodgkin’s lymphomaGerminal center B cell-likeActivated B cell-likeNext-generation sequencingImmunohistochemistryDiffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin's lymphoma that arises from the germinal center. It represents a heterogeneous ...
Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. Treatment of localized and advanced disease varies considerably. Below is a general treatment algorithm for DLBCL...
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392– 1399. 6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell ...
The diffuse large B cell lymphoma(DLBCL) is the most frequent type of non-Hodgkin lymphomas around the world and in all age groups. DLBCL is a heterogeneous diagnostic category consisting of molecularly distinct subtypes differing in gene expression, oncogenic aberrations and clinical outcomes. The ...
Figure 1. Development of lymphoma cell-of-origin (LCOO) assay classifier for diffuse large B-cell lymphoma (DLBCL) subtypes. A: Schematic of the experimental design. B: LCOO score cutoffs for activated B-cell (ABC), germinal center B-cell (GCB), and unclassifiable (UC) DLBCL subtypes. ...
Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell pr...
Overexpression of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM3) is related to the exhaustion of CD8+ tumor-infiltrating lymphocytes (TILs) in diffuse large B-cell lymphoma (DLBCL). However, the mechanism of TIM3-mediated CD8+TILs exhaustion in DLBCL remains poorly understood...
indistinguishable subtypes of diffuse large B-cell lymphoma (DLBCL): activated B-cell-like (ABC) and germinal-center B-cell-like (GCB) subtypes, by first developing a general lymphoma stable isotope labeling with amino acids in cell culture (SILAC) mix from heavy stable isotope-labeled cell ...
Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and di... RD Morin,K Mungall,E Pleasance,... - 《Blood》 被引量: 373发表: 2013年 Identification of microRNAs in the cerebrospinal fluid as ...